Artiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Wedbush in a research note issued on Friday, RTT News reports. They currently have a $18.00 price objective on the stock. Wedbush's target price would suggest a potential upside of 55.98% from the company's current price.

A number of other equities research analysts have also recently commented on ARTV. Cantor Fitzgerald assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price target on the stock. TD Cowen started coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a "buy" rating on the stock. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a "buy" rating and a $21.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Friday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Performance

ARTV traded up $0.24 during midday trading on Friday, reaching $11.54. The company had a trading volume of 76,292 shares, compared to its average volume of 116,193. Artiva Biotherapeutics has a 1 year low of $9.71 and a 1 year high of $16.00.

Insider Activity at Artiva Biotherapeutics

In related news, Director Yong-Jun Huh acquired 2,083,332 shares of the stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of $12.00 per share, with a total value of $24,999,984.00. Following the purchase, the director now directly owns 3,306,900 shares of the company's stock, valued at $39,682,800. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Yong-Jun Huh acquired 2,083,332 shares of the business's stock in a transaction on Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now directly owns 3,306,900 shares of the company's stock, valued at approximately $39,682,800. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio bought 416,666 shares of Artiva Biotherapeutics stock in a transaction dated Monday, July 22nd. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $4,999,992.00. Following the purchase, the insider now owns 1,936,637 shares of the company's stock, valued at approximately $23,239,644. The disclosure for this purchase can be found here.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.